Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms QUALIFY IPF
- Sponsors Boehringer Ingelheim
- 08 Mar 2019 Planned End Date changed from 19 Mar 2021 to 26 Mar 2021.
- 08 Mar 2019 Planned primary completion date changed from 19 Mar 2021 to 26 Mar 2021.
- 08 Mar 2019 Status changed from not yet recruiting to recruiting.